Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATOC PET for Neuroendocrine Tumors
NCT02359500Phase 1Terminated
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga 68-edotreotide in neuroendocrine tumors (NETs) and carcinoid tumor. Primary endpoint: Change in size of lesion at 1 month. Started Dec 2014; status: terminated.
02
Drugs
gallium Ga 68-edotreotide
03
Conditions
neuroendocrine tumors (NETs)carcinoid tumor
Beyond the preview
Go deeper on NCT02359500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359500.